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DETAILED SEARCH STRATEGY (from inception until May 30th, 2016) 
 
Pubmed/MEDLINE 
#1: ("Tumor Necrosis Factor-alpha"[Mesh] OR "Interleukin-1"[Mesh] OR "Interleukin-4"[Mesh] OR 
"Interleukin-6"[Mesh] OR "Interleukin-8"[Mesh] OR "Interleukin-10"[Mesh] OR "Interferons"[Mesh] OR 
"Receptors, Interleukin-2"[Mesh] OR "Chemokine CCL2"[Mesh] OR "Chemokine CCL3"[Mesh] OR 
"Chemokine CCL11"[Mesh] OR CXCL-8[Title/Abstract] OR CXCL-10[Title/Abstract]) Field: Title/Abstract 
#2: ("Depression"[Mesh] OR "Depressive Disorder"[Mesh] OR "Depressive Disorder, Major"[Mesh]) Field: 
Title/Abstract 
#3: #1 AND #2   
 
EMBASE Classic plus EMBASE through OVID (from 1947) and PsycInfo through OVID (from 1806) 
#1: (interleukin-2 or IL-2 or interleukin-1 or IL-1 or IL-4 or Interleukin-4 or IL-6 or Interleukin-6 or IL-8 or 
Interleukin-8 or IL-10 or Interleukin-10 or IFN-gamma or interferon gamma or TNF-alpha or tumor necrosis 
factor-alpha or IL-2 receptor or CCL-2 or CCL-3 or CXCL-8 or CCL-11 or CCL-10 or chemokine).ti,ab,kw 
#2: (depression or major depression or depressive disorder).ti,ab,kw 
#3: #1 and #2 
 
  
Supplementary Table S1. Excluded studies, with reasons. 
Reference Reason for exclusion 
Postal and Appenzeller, 2015 (1) Not an original study 
Oglodek, 2014 (2) Insufficient data for analysis 
Campos, 2014 (3) Animal study 
Camacho, 2014 (4) Not major depressive disorder 
Chocano-Bedoya, 2014 (5) Not major depressive disorder 
Anderson, 2013 (6) Not an original study 
Maes, 2014 (7) Not an original study 
Mitchell, 2013 (8) Insufficient data for analysis 
Doyle, 2013 (9) Not major depressive disorder 
Patas, 2014 (10) Clinical or psychiatric comorbidities 
Lucas, 2014 (11) Not major depressive disorder 
Yoshimura, 2013 (12) Not diagnostic study 
Poleshuck, 2013 (13) Not major depressive disorder 
Rotter, 2013 (14) Not diagnostic study 
Ranjbar, 2014 (15) Insufficient data for analysis 
Gazal, 2013 (16) Not diagnostic study 
Levandovski, 2013 (17) Not major depressive disorder 
Duivis, 2013 (18) Not major depressive disorder 
Isung, 2012 (19) Not major depressive disorder 
Belzeaux, 2012 (20) Did not measure cytokines 
Anisman and Hayley, 2012 (21) Not an original study 
Cattaneo, 2013 (22) Did not measure cytokines 
Raison, 2013 (23) Not diagnostic study 
Maes, 2012 (24) Not an original study 
Eyre and Baune, 2012 (25) Not an original study 
Abbasi, 2012 (26) Not diagnostic study 
Miller and Cole, 2012 (27) Not diagnostic study 
Silic, 2012 (28) Insufficient data for analysis 
Elomaa, 2012 (29) Clinical or psychiatric comorbidities 
Dome, 2012 (30) Not diagnostic study 
Caserta, 2011 (31) Not major depressive disorder 
Haastrup, 2012 (32) Insufficient data for analysis 
Yoon, 2012 (33) Insufficient data for analysis 
Martinez, 2012 (34) Measured cytokines in CSF 
Grassi-Oliveira, 2011 (35) Insufficient data for analysis 
Clark, 2013 (36) Not major depressive disorder 
Azar, 2012 (37) Not major depressive disorder 
Hennessy, 2011 (38) Animal study 
Rethorst, 2011 (39) Not major depressive disorder 
Su, 2011 (40) Not major depressive disorder 
Fluitman, 2011 (41) Insufficient data for analysis 
Janelidze, 2011 (42) Clinical or psychiatric comorbidities 
Lehto, 2010 (43) Not major depressive disorder 
Chen, 2010 (44) Not diagnostic study 
Jazayeri, 2010 (45) Not diagnostic study 
Himmerich, 2010 (46) Not diagnostic study 
Hallberg, 2010 (47) Insufficient data for analysis 
Zeugmann, 2010 (48) Insufficient data for analysis 
Koo, 2010 (49) Not major depressive disorder 
Baune, 2010 (50) Did not measure cytokines 
Eisenberger, 2010 (51) Not major depressive disorder 
Himmerich, 2010 (52) Not major depressive disorder 
Gabbay, 2009 (53) Insufficient data for analysis 
Hwang, 2009 (54) Did not measure cytokines 
Lehto, 2010 (55) Not an original study 
Koo and Duman, 2009 (56) Not an original study 
Bob, 2010 (57) No control group 
Ovaskainen, 2009 (58) Not major depressive disorder 
Capuron, 2009 (59) Clinical or psychiatric comorbidities 
Podlipny, 2010 (60) Not major depressive disorder 
Fazzino, 2009 (61) Not diagnostic study 
Milaneschi, 2009 (62) Not major depressive disorder 
Dimopoulos, 2008 (63) Clinical or psychiatric comorbidities 
Vaccarino, 2008 (64) Clinical or psychiatric comorbidities 
Himmerich, 2008 (65) Clinical or psychiatric comorbidities 
Wojciak, 2007 (66) Clinical or psychiatric comorbidities 
Mesquita, 2008 (67) Animal study 
Lehtimaki, 2008 (68) Small sample size (< 10) 
Stewart, 2008 (69) Not major depressive disorder 
Humphreys, 2006 (70) Small sample size (< 10) 
Hashioka, 2007 (71) Not major depressive disorder 
Rothenhausler, 2006 (72) Not major depressive disorder 
Pace, 2006 (73) Insufficient data for analysis 
Pucak and Kaplin, 2005 (74) Not an original study 
Ushiroyama, 2005 (75) Not major depressive disorder 
Fitzgerald, 2006 (76) Not diagnostic study 
Miller, 2005 (77) Not major depressive disorder 
Kubera, 2005 (78) In-vitro study 
Hestad, 2005 (79) Not an original study 
Alesci, 2005 (80) Small sample size (< 10) 
Schlatter, 2004 (81) In-vitro study 
Ushiroyama, 2004 (82) Not diagnostic study 
Himmerich, 2004 (83) Not major depressive disorder 
Andrade, 2004 (84) Not an original study 
Bouhuys, 2004 (85) Clinical or psychiatric comorbidities 
Merendino, 2004 (86) Small sample size (< 10) 
Brambilla, 2004 (87) Insufficient data for analysis 
Kubera, 2004 (88) In-vitro study 
Trzonkowski, 2004 (89) Clinical or psychiatric comorbidities 
Kast, 2003 (90) Not major depressive disorder 
Miller, 2003 (91) Not major depressive disorder 
Hestad, 2003 (92) Not major depressive disorder 
Schuld, 2003 (93) Previous administration of corticosteroid 
Penninx, 2003 (94) Clinical or psychiatric comorbidities 
Suarez, 2003 (95) Not major depressive disorder 
Miller, 2003 (96) Not major depressive disorder 
Tiemeier, 2003 (97) Not major depressive disorder 
Miller, 2002 (98) Not major depressive disorder 
Anisman, 2002 (99) Not an original study 
Benedetti, 2002 (100) Not major depressive disorder 
Anisman, 2002 (101) Not an original study 
Ushiroyama, 2002 (102) Not major depressive disorder 
Kubera, 2001 (103) Small sample size (< 10) 
Maes, 2001 (104) Not an original study 
Kagaya, 2001 (105) Small sample size (< 10) 
Schuld, 2001 (106) Not diagnostic study 
Maes, 1999 (107) Did not measure cytokines 
Miller, 1999 (108) Did not measure cytokines 
Reyes-Ortiz, 1999 (109) Not an original study 
Anisman, 1999 (110) In-vitro study 
Brambilla and Maggioni, 1998 
(111) 
Small sample size (< 10) 
Landmann, 1997 (112) In-vitro study 
Brambilla, 1997 (113) Not major depressive disorder 
Frommberger, 1997 (114) Small sample size (< 10) 
Seidel, 1996 (115) In-vitro study 
Maes, 1995 (116) Insufficient data for analysis 
Bauer, 1995 (117) Small sample size (< 10) 
Weizman, 1994 (118) In-vitro study 
Maes, 1993 (119) In-vitro study 
Maes, 1993 (120) Did not measure cytokines 
Maes, 1991 (121) In-vitro study 
Maes, 1990 (122) Previous administration of corticosteroid 
Fonseka, 2015 (123) Not an original study 
Bahrini, 2015 (124) Abstract. Data unavailable 
Beasley, 2014 (125) Abstract. Data unavailable 
Muller, 2014 (126) Not an original study 
Yang, 2015 (127) Not an original study 
Fasick, 2015 (128) Not an original study 
Hiles, 2015 (129) Not major depressive disorder 
Bot, 2015 (130) Clinical or psychiatric comorbidities 
Pandey, 2015 (131) Did not measure cytokines 
Rapaport, 2015 (132) Not diagnostic study 
Jangpangi, 2012 (133) Abstract. Data unavailable 
Fonseka, 2014 (134) Not an original study 
Ho, 2014 (135) Not an original study 
Vogelzangs, 2014 (136) Not major depressive disorder 
Brunoni, 2014 (137) Not diagnostic study 
Quak, 2014 (138) Not major depressive disorder 
Figueroa, 2013 (139) Not major depressive disorder 
Mishra, 2015 (140) Abstract. Data unavailable 
Audet, 2014 (141) Not an original study 
Tully, 2015 (142) Not major depressive disorder 
Duseja, 2015 (143) Animal study 
Glaus, 2014 (144) Clinical or psychiatric comorbidities 
Matsushima, 2015 (145) Not major depressive disorder 
Grudet, 2014 (146) Not major depressive disorder 
Chang, 2014 (147) Not major depressive disorder 
Olajossy, 2014 (148) Clinical or psychiatric comorbidities 
Kloiber, 2012 (149) Abstract. Data unavailable 
Hughes, 2012 (150) Abstract. Data unavailable 
Halaris, 2012 (151) Abstract. Data unavailable 
Dantzer, 2012 (152) Not an original study 
Thiagarajah, 2014 (153) Did not measure cytokines 
McDade, 2013 (154) Not major depressive disorder 
Goldschmied, 2013 (155) Abstract. Data unavailable 
Bizik, 2014 (156) Insufficient data for analysis 
Cho, 2014 (157) Not major depressive disorder 
Arts, 2014 (158) Abstract. Data unavailable 
Ajilore, 2014 (159) Abstract. Data unavailable 
Halaris, 2014 (160) Insufficient data for analysis 
Pallavi, 2014 (161) Abstract. Data unavailable 
Toups, 2014 (162) Insufficient data for analysis 
Momeni, 2014 (163) Not major depressive disorder 
Raghuvanshi, 2013 (164) Not diagnostic study 
Boufidou, 2014 (165) Abstract. Data unavailable 
Lee, 2013 (166) Did not measure cytokines 
Hennings, 2013 (167) Clinical or psychiatric comorbidities 
Molteni, 2013 (168) Animal study 
Ajilore, 2012 (169) Abstract. Data unavailable 
Prossin, 2012 (170) Not diagnostic study 
Ninan, 2012 (171) Did not measure cytokines 
Lichtblau, 2013 (172) Not an original study 
Rybka, 2013 (173) Abstract. Data unavailable 
Yoshimura and Nakamura, 2013 
(174) 
Abstract. Data unavailable 
Schilling Panizzutti, 2013 (175) Abstract. Data unavailable 
Hughes, 2013 (176) Not major depressive disorder 
Pavon, 2013 (177) Abstract. Full text available. 
Zeugmann, 2013 (178) Not major depressive disorder 
Byrne, 2013 (179) Not major depressive disorder 
Park and Baek, 2013 (180) Not major depressive disorder 
Stelzhammer, 2013 (181) Small sample size (< 10) 
Pantovic, 2013 (182) Insufficient data for analysis 
Khan, 2013 (183) Not an original study 
Niedzwiecki, 2013 (184) Abstract. Data unavailable 
Magalhaes, 185) Abstract. Data unavailable 
Iwata, 2013 (186) Not an original study 
Mishra, 2013 (187) Abstract. Data unavailable 
De Mello, 2012 (188) Not major depressive disorder 
Ruljancic, 2011 (189) Abstract. Data unavailable 
Raison, 2012 (190) Not diagnostic study 
Rawdin, 2012 (191) Abstract. Data unavailable 
Fagundes, 2012 (192) Not major depressive disorder 
Tynan, 2012 (193) Not major depressive disorder 
Groer, 2012 (194) Not major depressive disorder 
Halaris, 2012 (195) Abstract. Data unavailable 
Halaris, 2012 (196) Abstract. Data unavailable 
Rybka, 2012 (197) Abstract. Data unavailable 
Voderholzer, 2012 (198) Not diagnostic study 
Fang, 2012 (199) Animal study 
Fareed, 2010 (200) Abstract. Data unavailable 
Lazary, 2012 (201) Did not measure cytokines 
Fischer, 2012 (202) Not major depressive disorder 
Leonard, 2012 (203) Not an original study 
Erhardt, 2012 (204) Did not measure cytokines 
Karaoulanis, 2012 (205) Clinical or psychiatric comorbidities 
Einvik, 2012 (206) Clinical or psychiatric comorbidities 
Behr, 2012 (207) Abstract. Data unavailable 
Quinones, 2012 (208) Insufficient data for analysis 
Leonard, 2012 (209) Not an original study 
Bay-Richter, 2012 (210) Not major depressive disorder 
Cattaneo, 2012 (211) Did not measure cytokines 
Vogelzangs, 2012 (212) Not major depressive disorder 
Euteneuer, 2012 (213) Clinical or psychiatric comorbidities 
Leonard and Maes, 2012 (214) Not an original study 
Hayley, 2011 (215) Not an original study 
Kang, 2011 (216) Animal study 
Yang, 2011 (217) Did not measure cytokines 
Blume, 2011 (218) Not an original study 
Toups, 2011 (219) Insufficient data for analysis 
Kemp, 2011 (220) Not diagnostic study 
Hodes, 2011 (221) Animal study 
Pavon Romero, 2011 (222) Abstract. Data unavailable 
Krogh and Nordentoft, 2011 (223) Abstract. Data unavailable 
Halaris, 2011 (224) Abstract. Data unavailable 
Pavon, 2011 (225) Did not measure cytokines 
Gibney, 2011 (226) Animal study 
Henje Blom, 2011 (227) Clinical or psychiatric comorbidities 
Casale, 2011 (228) Did not measure cytokines 
Gilbey, 2011 (229) Did not measure cytokines 
Baghai, 2011 (230) Clinical or psychiatric comorbidities 
Blume, 2011 (231) Abstract. Data unavailable 
Grassi-Oliveira, 2011 (232) Abstract. Data unavailable 
Aschbacher, 2011 (233) Not major depressive disorder 
Brietzke, 2011 (234) Not major depressive disorder 
Penninx, 2011 (235) Abstract. Data unavailable 
Chung, 2009 (236) Abstract. Data unavailable 
Caruncho and Rivera-Baltanas, 
2010 (237) 
Not an original study 
Forti, 2010 (238) Clinical or psychiatric comorbidities 
Himmerich, 2010 (239) Insufficient data for analysis 
DellaGioia and Hannestad, 2010 
(240) 
Not major depressive disorder 
Vogelzangs, 2010 (241) Clinical or psychiatric comorbidities 
Carvalho, 2010 (242) Abstract. Data unavailable 
Pace, 2010 (243) Not diagnostic study 
Prossin, 2010 (244) Not diagnostic study 
Rush, 2010 (245) Abstract. Data unavailable 
Bay-Richter, 2010 (246) Animal study 
O'Donovan, 2010 (247) Abstract. Full text available. 
Karrenbauer, 2010 (248) Animal study 
Yoshimura, 2010 (249) Abstract. Data unavailable 
Christopoulos, 2010 (250) Abstract. Data unavailable 
Chang, 2010 (251) Abstract. Data unavailable 
Khairova, 2009 (252) Not an original study 
MacKay, 2009 (253) Not diagnostic study 
Anisman, 2009 (254) Not an original study 
Dantzer, 2009 (255) Not an original study 
Yasui, 2009 (256) Not major depressive disorder 
Sekiyama, 2009 (257) Abstract. Data unavailable 
Halaris, 2009 (258) Not an original study 
Wang, 2009 (259) Clinical or psychiatric comorbidities 
Postolache, 2009 (260) Not an original study 
Talaie, 2008 (261) Not major depressive disorder 
Berthold-Losleben and 
Himmerich, 2008 (262) 
Not an original study 
Kim, 2007 (263) Study sample treated with monoclonal antibody 
Kim, 2007 (264) Not major depressive disorder 
Schlatter, 2006 (265) In-vitro study 
Tsao, 2006 (266) Did not measure cytokines 
Schiepers, 2005 (267) Not an original study 
Schlatter, 2004 (268) In-vitro study 
Hayley, 2003 (269) Not an original study 
Jozuka, 2003 (270) Insufficient data for analysis 
Kenis and Maes, 2002 (271) Not an original study 
Anisman and Merali, 2002 (272) Not an original study 
Rief, 2001 (273) Clinical or psychiatric comorbidities 
Schlatter, 2001 (274) In-vitro study 
Vetta, 2001 (275) Insufficient data for analysis 
Rothermundt, 2001 (276) Insufficient data for analysis 
Herran, 2000 (277) Insufficient data for analysis 
Kubera, 2000 (278) In-vitro study 
Lutgendorf, 1999 (279) Not major depressive disorder 
Licinio and Wong, 1999 (280) Not an original study 
Haack, 1999 (281) Clinical or psychiatric comorbidities 
Kusunoki, 1999 (282) Insufficient data for analysis 
Song, 1998 (283) Small sample size (< 10) 
Connor and Leonard, 1998 (284) Not an original study 
Maes, 1996 (285) Insufficient data for analysis 
Sluzewska, 1995 (286) Clinical or psychiatric comorbidities 
Maes, 1995 (287) Did not measure cytokines 
Maes, 1995 (288) Previous administration of corticosteroid 
Baron, 1993 (289) Clinical or psychiatric comorbidities 
Maes, 1992 (290) Insufficient data for analysis 
Guidi, 1991 (291) In-vitro study 
Darko, 1989 (292) Did not measure cytokines 
Pallavi, 2015 (293) Insufficient data for analysis 
Noto, 2015 (294) Not an original study 
Zalli, 2015 (295) Not major depressive disorder 
Vogelzangs, 2014 (296) Insufficient data for analysis 
Savitz, 2015 (297) Did not measure cytokines 
Hufner, 2015 (298) Did not measure cytokines 
Prather, 2015 (299) Not major depressive disorder 
Varma, 2014 (300) Not an original study 
Iacob, 2014 (301) Did not measure cytokines 
Rethorst, 2013 (302) Not diagnostic study 
Liatis, 2013 (303) Not major depressive disorder 
Lamers, 2013 (304) Not major depressive disorder 
Bermudez, 2012 (305) Not an original study 
Baune, 2012 (306) Not major depressive disorder 
Fignole Lofton, 2012 (307) Not major depressive disorder 
Blom, 2012 (308) Clinical or psychiatric comorbidities 
Hafner, 2011 (309) Not major depressive disorder 
Lotrich, 2011 (310) Not an original study 
Carvalho, 2010 (311) Not major depressive disorder 
Gabbay, 2009 (312) Insufficient data for analysis 
Gimeno, 2009 (313) Not diagnostic study 
Heiser, 2008 (314) Previous administration of corticosteroid 
Johnson, 2009 (315) Not major depressive disorder 
Clerici, 2009 (316) Did not measure cytokines 
Su, 2009 (317) Not major depressive disorder 
Dinan, 2009 (318) Not an original study 
Capuron, 2008 (319) Insufficient data for analysis 
Aguilar-Zavala, 2008 (320) Not major depressive disorder 
Bremmer, 2008 (321) Clinical or psychiatric comorbidities 
Steptoe, 2003 (322) Not major depressive disorder 
Nunes, 2002 (323) Insufficient data for analysis 
Darko, 1988 (324) In-vitro study 
Lanquillon, 2000 (325) In-vitro study 
Dentino, 1999 (326) Not major depressive disorder 
Sluzewska, 1997 (327) Not major depressive disorder 
Berk, 1997 (328) Not major depressive disorder 
Eller, 2009 (329) Not an original study 
Kabanchik, 2004 (330) Data unavailable 
Kraus, 2002 (331) Not diagnostic study 
Zubareva, 2001 (332) Small sample size (< 10) 
Kubera, 2000 (333) Data unavailable 
Castilla-Cortazar, 1998 (334) In-vitro study 
Zhang, 2015 (335) Clinical or psychiatric comorbidities 
Catena-Dell'Osso, 2013 (336) Not an original study 
Catena-Dell'Osso, 2011 (337) Not an original study 
Sun, 2010 (338) Not diagnostic study 
Himmerich, 2009 (339) Not an original study 
Cattaneo, 2008 (340) Did not measure cytokines 
Adler, 2008 (341) Not an original study 
Craddock and Thomas, 2006 
(342) 
Not an original study 
Qi, 2005 (343) Insufficient data for analysis 
Kaminska, 2002 (344) Data unavailable 
Androsova, 2001 (345) Clinical or psychiatric comorbidities 
Nebbia, 2000 (346) Not an original study 
West and Maes, 1999 (347) Not an original study 
Jozuka, 2000 (348) Not major depressive disorder 
Liu, 2015 (349) Not diagnostic study 
Liu, 2015 (350) 
MDD diagnosis not using DSM, ICD or a validated 
screening instrument (CCMD-3 Chinese criteria) 
Arts, 2015 (351) Not major depressive disorder 
Liu, 2015 (352) 
MDD diagnosis not using DSM, ICD or a validated 
screening instrument (CCMD-3 Chinese criteria) 
Hashimoto, 2015 (353) Insufficient data for analysis 
Demir, 2015 (354) Did not measure cytokines 
Walker, 2015 (355) Animal study 
Moreira, 2015 (356) Not diagnostic study 
Yu, 2015 (357) Not diagnostic study 
Vinberg, 2015 (358) Abstract. Data unavailable 
Nassan, 2015 (359) Abstract. Data unavailable 
Sharma, 2015 (360) Abstract. Data unavailable 
Goldsmith, 2015 (361) Abstract. Data unavailable 
Haroon, 2015 (362) Abstract. Data unavailable 
Costi, 2015 (363) Abstract. Data unavailable 
Dunjic-Kostic, 2015 (364) Abstract. Data unavailable 
Mischoulon, 2015 (365) Abstract. Data unavailable 
Gazal, 2015 (366) Clinical or psychiatric comorbidities 
MacIukiewicz, 2015 (367) Did not measure cytokines/chemokines 
Becking, 2015 (368) No control group 
Rethorst, 2015 (369) Not diagnostic study 
Brown, 2016 (370) Not major depressive disorder 
Rethorst, 2015 (371) Not diagnostic study 
Schmidt, 2016 (372) Insufficient data for analysis 
Dahl, 2016 (373) Not diagnostic study 
Del Grande da Silva, 2016 (374) Not diagnostic study 
Rapaport, 2016 (375) Not diagnostic study 
Euteneuer, 2016 (376) Not diagnostic study 
Glaus, 2016 (377) Abstract. Data unavailable 
Kiraly, 2016 (378) Abstract. Data unavailable 
Oses, 2016 (379) Not diagnostic study 
Park, 2016 (380) Clinical or psychiatric comorbidities 
Goldsmith, 2016 (381) Not major depressive disorder 
Baune, 2016 (382) Abstract. Data unavailable 
Schmidt, 2016 (383) Not diagnostic study 
Lai, 2016 (384) Not major depressive disorder 
Vogelzangs, 2014 (385) Clinical or psychiatric comorbidities 
Euteneuer, 2012 (386) Clinical or psychiatric comorbidities 
Euteneuer, 2011 (387) Clinical or psychiatric comorbidities 
Pike and Irwin, 2006 (388) Clinical or psychiatric comorbidities 
Bai, 2015 (389) Clinical or psychiatric comorbidities 
Danneh, 2014 (390) Clinical or psychiatric comorbidities 
Rawdin, 2013 (391) Clinical or psychiatric comorbidities 
Wolkowitz, 2011 (392) Clinical or psychiatric comorbidities 
Marques-Deak, 2007 (393) Clinical or psychiatric comorbidities 
Shelton, 2015 (394) Clinical or psychiatric comorbidities 
Manoharan, 2016 (395) Clinical or psychiatric comorbidities 
Teunissen, 2016 (396) Clinical or psychiatric comorbidities 
Cassano, 2016 (397) Clinical or psychiatric comorbidities 
 
 











score N Age BMI 
% females/ 
% smokers 
















75.0/NA 40 54.0 ± 9.8 N/A 92.5/NA DSM-IV 
(NA) 













Baek and Park, 
2013 (400) 
(South Korea) 
















Y 30 39.2 ± 
9.2 
NA 60.0/46.7 65 39.7 ± 
12.9 
N/A 58.5/38.5 DSM-IV 
(MINI) 












59.5/NA 109 42.0 ± 
13.8 
22.5 ± 4.2 76.1/NA DSM-IV 
(MINI) 








Y 23 33.6 ± 
12.5 
NA 87.0/NA 23 33.8 ± 
12.8 
N/A 87.0/NA DSM-IV 
(NA) 












66.7/NA 15 40.7 ± 
12.7 
25.3 ±  4.9 66.7/NA DSM-IV 
(SCID) 








N 20 40.1 ± 
11.0 
NA 60.0/NA 24 46.8 ± 
13.0 
N/A 66.7/NA DSM-IV-TR 
(MINI) 












71.4/NA 19 49.7 ± 3.8 28.9 ±  1.6 73.7/NA ICD-10 
(SCID) 








N 36 NA NA 44.4/NA 38 N/A NA 57.9/NA DSM-IV-TR 
(MINI) 





Dahl, 2014 (408) 
(Norway) 




55.9/NA 50 40.0 ± 
12.0 
25.8 ±  5.5 76.0/NA DSM-IV 
(MINI) 












54.5/NA 12 38.4 ± 
11.0 









Dinan, 2009 (410) 
(Ireland) 







Diniz, 2010 (411) 
(Brazil) 
N 39 70.2 ± 
5.3 
NA 84.6/NA 28 70.4 ± 4.4 N/A 78.6/NA DSM-IV 
(SCID) 





Diniz, 2010 (412) 
(Brazil) 
Y 44 69.5 ± 
7.1 
NA 86.4/NA 23 70.2 ± 4.9 N/A 82.6/NA DSM-IV 
(NA) 












87.5/62.5 33 40.6 ± 
10.6 
















56.4/NA 47 51.0 ± 7.3 22.4 ±  1.1 55.3/NA DSM-IV 
(NA) 













75.6/NA 42 69.7 ± 7.9 25.6 ±  4.4 66.7/NA DSM-IV 
(SCID) 





Eller, 2008 (416) 
(Estonia) 
Y 45 32.9 ± 
14.1 
NA 57.8/NA 100 32.1 ± 
11.9 
NA 65.0/NA DSM-IV 
(MINI) 





Eller, 2009 (417) 
(Estonia) 
Y 45 32.9 ± 
14.1 
NA 57.8/NA 28 31.2 ± 9.5 24.3 ±  3.5 60.7/NA DSM-IV 
(MINI) 
























Y 16 44.0 ± 
11.6 
NA 56.3/NA 16 51.1 ± 
11.0 
NA 75.0/NA DSM-IV 
(SCID) 








Y 32 45.2 ± 
11.6 
NA 75.0/NA 30 48.3 ± 9.7 NA 80.0/NA DSM-IV 
(SCID) 





Frodl, 2012 (421) 
(Ireland) 
Y 43 37.0 ± 
13.7 
NA 58.1/NA 40 41.4 ± 
10.9 
NA 60.0/NA DSM-IV 
(SCID) 








N 12 31.0 ± 
4.0 
NA 50.0/NA 12 46.0 ± 
16.0 
NA 83.3/NA DSM-III-R 
(SCID) 




























NA/NA 30 39.2 ± 8.7 25.8 ±  2.3 NA/NA DSM-IV 
(SCID) 




























66.7/NA 31 35.0 ± 9.0 24.6 ±  0.7 67.7/NA DSM-IV-TR 
(MINI) 





Ho, 2015 (426) 
(Taiwan) 
N 24 26.5 ± 
3.2 
NA 0.0/0.0 26 23.2 ± 3.2 NA 0.0/NA DSM-IV 
(NA) 








Y 30 30.0 ± 
9.0 
NA 46.7/NA 30 38.0 ± 
13.0 










Y 15 38.2 ± 
12.0 
NA NA/NA 37 39.1 ± 
12.3 
NA 73.0/NA DSM-IV 
(NA) 





Huang and Lee, 
2007 (429) 
(Taiwan) 




62.5/NA 42 38.0 ± 8.2 22.5 ±  4.4 71.4/NA DSM-IV 
(SCID) 












56.4/28.2 39 41.9 ± 
11.2 









Hung, 2007 (431) 
(Taiwan) 




0.0/NA 35 22.7 ± 0.3 21.9 ±  0.3 0.0/NA DSM-IV 
(NA) 






Y 10 33.9 ± 
9.8 
NA NA/NA 17 40.3 ± 
15.1 
NA 23.5/NA DSM-III-R 
(NA) 








Y 37 44.6 ± 
13.9 
NA 70.3/NA 37 45.1 ± 
14.1 
NA 70.3/NA DSM-IV 
(SCID) 





Kahl, 2005 (433) 
(Germany) 









Kahl, 2015 (434) 
(Germany) 




47.4/15.8 27 43.4 ± 8.7 26 ±  4.2 44.4/44.4 DSM-IV 
(SCID) 








N 18 45.0 ± 
9.5 
NA 55.6/22.2 55 49.6 ± 8.2 NA 36.4/27.3 DSM-IV-TR 
(MINI) 





Kim, 2008 (436) 
(South Korea) 




62.5/NA 69 35.0 ± 
11.0 
21.6 ±  3.4 65.2/NA DSM-IV 
(SCID) 





Kim, 2013 (437) 
(Korea) 













Krogh, 2014 (438) 
(Denmark) 




59.6/NA 112 41.6 ± 
11.5 
26.3 ±  5.9 62.5/NA DSM-IV 
(MINI) 





Lee, 2009 (439) 
(Korea) 











Leo, 2006 (440) 
(Italy) 













Li, 2013 (441) 
(China) 




78.1/0.0 64 32.1 ± 6.8 21.3 ± 2.2 78.1/0.0 DSM-IV-TR 
(SCID) 





Maes, 1995 (442) 
(USA) 
N 38 33.8 ± 
1.5 
NA 44.7/NA 61 36.6 ± 1.3 NA 41.0/NA DSM-III-R 
(NA) 





Maes, 1995 (443) 
(NA) 
N 34 31.9 ± 
6.8 







Maes, 1995 (444) 
(USA) 
N 28 34.4 ± 
15.1 
NA 35.7/NA 13 35.2 ± 
12.2 
NA 46.2/NA DSM-III-R 
(SADS) 
NA Whole blood 
(ELISA) 
4 
Maes, 1997 (445) 
(Belgium) 
Y 15 47.5 ± 
15.0 
NA 33.3/NA 35 50.3 ± 
13.9 
NA 45.7/NA DSM-III-R 
(NA) 





Maes, 2012 (446) 
(Belgium) 
Y 35 42.5 ± 
12.4 
NA 65.7/NA 109 43.0 ± 
11.0 
NA 54.1/NA DSM-IV-TR 
(NA) 





Maes, 2012 (447) 
(Belgium) 
N 26 42.1 ± 
12.8 
NA 57.7/NA 85 42.0 ± 
11.0 
NA 57.6/NA DSM-IV-TR 
(SCID) 








Y 15 42.0 ± 
10.9 
NA 53.3/NA 28 47.3 ± 
11.3 







Mota, 2013 (449) 
(Brazil) 














Y 18 40.3 ± 
9.2 
NA 0.0/0.0 22 44.4 ± 7.5 NA 0.0/59.1 DSM-IV 
(SCID) 





Myint, 2005 (451) 
(Korea) 




67.5/NA 40 40.7 ± 
15.5 
21.4 ± 2.5 67.5/NA DSM-IV 
(NA) 








N 24 35.6 ± 
9.0 
NA 58.3/NA 44 44.4 ± 
14.2 
NA 68.2/NA DSM-IV 
(SCID) 












70.8/NA 74 51.3 ± 4.2 26.6 ± 5.6 70.3/NA DSM-IV-TR 
(MINI) 





Owen, 2001 (454) 
(United Kingdom) 
Y 20 NA NA NA/NA 20 NA NA NA/NA DSM-IV 
(NA) 












67.4/NA 36 42.5 ± 9.8 27.7 ± 5.8 36.1/NA DSM-IV 
(MINI) 








Y 33 32.3 ± 
10.8 
NA 84.8/NA 33 33.6 ± 
10.2 
NA 84.8/NA DSM-IV 
(MINI) 





Piletz, 2009 (457) 
(USA) 




82.4/0.0 22 39.4 ± 1.9 28.1 ± 1.4 86.4/18.2 DSM-IV 
(SCID) 














Irwin, 1996 (459) 
(USA) 
Y 15 44.2 ± 
10.3 
NA 0.0/NA 15 44.6 ± 9.9 NA 0.0/NA DSM-III-R 
(SCID) 








Y 43 44.5 ± 
10.0 
NA NA/NA 43 44.5 ± 
10.0 
NA 65.1/37.2 DSM-IV 
(CIDI) 












33.3/NA 32 34.8 ± 
11.1 


























Y 39 37.9 ± 
10.9 
NA 69.2/NA 39 39.9 ± 9.4 NA 69.2/NA DSM-III-R 
(NA) 





Shen, 2010 (464) 
(China) 
N 40 40.3 ± 
10.1 
NA 50.0/NA 34 42.5 ± 
12.1 
NA 47.1/NA DSM-IV 
(NA) 








N 11 39.2 ± 
4.2 
NA 72.7/NA 22 42.0 ± 5.6 NA 90.9/NA DSM-III-R 
(NA) 








Y 15 NA NA NA/NA 49 42.3 ± 6.5 NA 81.6/NA DSM-III-R 
(NA) 





Song, 2009 (467) 
(China) 
N 30 33.2 ± 
11.5 
NA NA/NA 32 34.0 ± 
13.0 
NA 56.3/NA DSM-IV 
(SCID) 








N 54 47.4 ± 
10.0 
NA 74.1/NA 33 50.1 ± 9.1 26.8 ± 2.8 84.8/NA DSM-IV 
(MINI) 








Y 25 34.3 ± 
7.8 
NA 48.0/NA 23 34.8 ± 7.4 NA 47.8/NA DSM-IV 
(NA) 







N 21 74.9 ± 
7.0 
NA 57.1/NA 19 76.4 ± 7.3 NA 68.4/NA DSM-IV 
(NA) 





Tuglu, 2003 (471) 
(Turkey) 
Y 17 37.1 ± 
11.1 
NA 35.3/NA 26 39.4 ± 
14.7 
NA 42.3/69.2 DSM-IV 
(SCID) 









NA/NA 22 81.0 ± 
10.8 
20.9 ± 2.3 NA/NA DSM-IV 
(NA) 





Yang, 2005 (473) 
(China) 















Yang, 2007 (474) 
(China) 




69.6/NA 33 42.1 ± 2.3 22.8 ± 0.57 72.7/NA DSM-IV 
(NA) 








N 30 43.2 ± 
12.7 
NA 56.7/NA 51 39.8 ± 
11.8 
NA 58.8/NA DSM-IV 
(MINI) 








Y 20 36.7 ± 
10.1 
NA 65.0/NA 20 39.2 ± 
10.6 
NA 65.0/NA DSM-IV 
(NA) 





Zoga, 2014 (477) 
(Greece) 




100.0/NA 40 51.1 ± 
10.7 
26.6 ± 5.8 100.0/NA DSM-IV-TR 
(SCID) 





Continuous variables are presented as mean ± SD. 
  
Supplementary Table S3. Meta-regressions of inflammatory markers in subjects with MDD versus healthy controls (HC). 
Variable 
N Meta-regression Meta-regression 
Studies MDD Controls Slope 95% CI P-value Intercept z P-value 
IL-6           
BMI mean (MDD) 17 721 557 0.050 -0.061 0.161 0.374 -0.642 -0.448 0.654 
BMI mean (HC) 16 688 503 0.075 -0.052 0.201 0.248 -1.200 -0.754 0.451 
BMI difference (MDD-HC) 16 688 503 -0.026 -0.236 0.184 0.810 0.645 4.455 < 0.001 
Publication year 42 1587 1183 -0.009 -0.029 0.012 0.416 17.909 0.843 0.399 
Sample size 42 1587 1183 0.004 -0.001 0.008 0.123 0.370 2.093 0.036 
Age mean (MDD) 39 1485 1093 0.011 -0.006 0.028 0.212 0.149 0.405 0.686 
Age mean (HC) 38 1436 1078 0.009 -0.008 0.025 0.297 0.236 0.722 0.470 
Age difference (MDD-HC) 38 1436 1078 0.013 -0.026 0.053 0.511 0.532 6.023 < 0.001 
Gender % female (MDD) 42 1587 1183 0.002 -0.004 0.008 0.505 0.493 2.427 0.015 
Gender % female (HC) 41 1538 1168 0.005 -0.001 0.012 0.091 0.292 1.533 0.125 
Gender % female difference (MDD-HC) 41 1538 1168 -0.010 -0.019 0.000 0.046 0.640 9.559 < 0.001 
Depression severity 33 1313 955 0.007 -0.001 0.015 0.088 -0.097 -0.222 0.825 
Country latitude 41 1531 1149 0.001 -0.003 0.006 0.637 0.580 5.721 < 0.001 
% Drug free 35 1325 959 0.000 -0.004 0.004 0.937 0.586 3.450 0.001 
Quality score 42 1587 1183 0.023 -0.083 0.130 0.668 0.524 2.224 0.026 
TNF-α           
BMI mean (MDD) 22 879 930 -0.048 -0.215 0.119 0.575 1.979 0.927 0.354 
BMI mean (HC) 20 818 831 -0.040 -0.177 0.097 0.563 1.879 1.067 0.286 
BMI difference (MDD-HC) 20 818 831 0.053 -0.213 0.318 0.697 0.873 3.780 < 0.001 
% Smokers (MDD) 10 440 506 0.020 0.004 0.037 0.017 0.194 0.647 0.518 
% Smokers (HC) 10 440 513 0.020 0.002 0.038 0.032 0.282 1.194 0.233 
Publication year 42 1620 1457 -0.071 -0.148 0.006 0.070 143.482 1.820 0.069 
Sample size 42 1620 1457 -0.003 -0.009 0.004 0.447 0.884 2.963 0.003 
Age mean (MDD) 39 1518 1367 0.027 -0.001 0.055 0.062 -0.503 -0.803 0.422 
Age mean (HC) 39 1518 1367 0.028 -0.001 0.057 0.056 -0.491 -0.812 0.417 
Age difference (MDD-HC) 39 1518 1367 -0.004 -0.100 0.092 0.937 0.642 3.625 < 0.001 
Gender % female (MDD) 41 1598 1434 0.004 -0.008 0.015 0.506 0.355 0.883 0.377 
Gender % female (HC) 39 1530 1389 0.004 -0.008 0.016 0.549 0.434 1.076 0.282 
Gender % female difference (MDD-HC) 39 1530 1389 0.001 -0.019 0.021 0.928 0.660 4.969 < 0.001 
Depression severity 35 1367 1235 0.004 -0.008 0.016 0.526 0.189 0.268 0.789 
Country latitude 41 1598 1434 0.002 -0.008 0.013 0.637 0.524 2.368 0.018 
% drug free 30 1156 1095 -0.004 -0.012 0.004 0.373 0.875 2.435 0.015 
Quality score 42 1620 1457 -0.241 -0.469 -0.013 0.038 1.608 3.433 0.001 
IL-1β           
BMI mean (MDD) 10 407 354 0.265 0.054 0.476 0.014 -6.692 -2.470 0.013 
BMI mean (HC) 11 447 374 0.225 -0.025 0.475 0.078 -5.527 -1.745 0.081 
BMI difference (MDD-HC) 10 407 354 -0.040 -0.658 0.579 0.900 -0.040 -0.147 0.883 
Publication year 22 779 727 -0.011 -0.084 0.062 0.773 21.715 0.289 0.772 
Sample size 22 779 727 0.003 -0.011 0.018 0.665 -0.189 -0.350 0.726 
Age mean (MDD) 21 759 707 0.024 -0.005 0.053 0.108 -0.999 -1.542 0.123 
Age mean (HC) 21 759 707 0.027 -0.001 0.055 0.055 -1.085 -1.826 0.068 
Age difference (MDD-HC) 21 759 707 -0.098 -0.234 0.038 0.158 0.177 0.802 0.423 
Gender % female (MDD) 21 759 707 -0.003 -0.024 0.018 0.773 0.214 0.281 0.779 
Gender % female (HC) 19 684 634 -0.006 -0.029 0.017 0.611 0.347 0.447 0.655 
Gender % female difference (MDD-HC) 19 684 634 0.016 -0.030 0.061 0.498 -0.121 -0.491 0.624 
Depression severity 19 636 594 -0.007 -0.024 0.010 0.444 0.712 0.747 0.455 
Country latitude 21 760 706 0.000 -0.016 0.016 0.971 -0.017 -0.053 0.958 
% drug free 18 661 627 -0.005 -0.021 0.010 0.484 0.366 0.515 0.606 
Quality score 22 779 727 -0.138 -0.486 0.21 0.436 0.586 0.796 0.426 
IFN-γ           
BMI mean (MDD) 11 513 606 0.207 0.013 0.401 0.037 -5.346 -2.130 0.033 
BMI mean (HC) 10 480 552 0.138 0.014 0.262 0.029 -3.654 -2.227 0.026 
BMI difference (MDD-HC) 10 480 552 -0.221 -0.488 0.047 0.106 -0.243 -0.839 0.401 
Publication year 17 700 770 0.181 0.047 0.315 0.008 -364.147 -2.647 0.008 
Sample size 17 700 770 0.011 0.004 0.018 0.002 -1.439 -3.859 < 0.001 
Age mean (MDD) 17 700 770 0.062 0.005 0.120 0.034 -2.970 -2.484 0.013 
Age mean (HC) 17 700 770 0.062 0.005 0.120 0.034 -2.873 -2.494 0.013 
Age difference (MDD-HC) 17 700 770 0.001 -0.209 0.211 0.991 -0.484 -1.592 0.111 
Gender % female (MDD) 17 700 770 -0.002 -0.026 0.023 0.891 -0.366 -0.415 0.678 
Gender % female (HC) 15 632 725 -0.003 -0.030 0.024 0.822 -0.266 -0.286 0.775 
Gender % female difference (MDD-HC) 15 632 725 0.001 -0.054 0.056 0.966 -0.471 -1.462 0.144 
Depression severity 15 590 660 -0.004 -0.026 0.019 0.751 -0.186 -0.153 0.878 
Country latitude 17 700 770 0.003 -0.011 0.018 0.670 -0.560 -1.783 0.075 
% drug free 14 551 621 -0.014 -0.040 0.012 0.294 0.657 0.537 0.591 
Quality score 17 700 770 -0.375 -0.870 0.120 0.138 1.001 0.976 0.329 
IL-10           
BMI mean (MDD) 10 371 481 -0.253 -0.542 0.037 0.087 7.294 1.870 0.062 
Publication year 17 608 675 0.007 -0.091 0.106 0.883 -14.479 -0.143 0.886 
Sample size 17 608 675 -0.001 -0.010 0.007 0.775 0.476 1.160 0.246 
Age mean (MDD) 17 608 675 -0.023 -0.089 0.043 0.491 1.310 0.957 0.339 
Age mean (HC) 17 608 675 -0.036 -0.111 0.039 0.345 1.733 1.193 0.233 
Age difference (MDD-HC) 17 608 675 0.022 -0.136 0.179 0.785 0.319 0.975 0.330 
Gender % female (MDD) 17 608 675 0.005 -0.020 0.030 0.684 0.038 0.044 0.965 
Gender % female (HC) 15 540 630 0.007 -0.020 0.034 0.629 0.070 0.080 0.936 
Gender % female difference (MDD-HC) 15 540 630 -0.011 -0.057 0.036 0.651 0.532 1.901 0.057 
Depression severity 16 578 645 -0.002 -0.022 0.018 0.866 0.585 0.520 0.603 
Country latitude 17 608 675 0.005 -0.015 0.024 0.650 0.224 0.537 0.591 
% drug free 13 426 519 0.003 -0.014 0.020 0.718 0.146 0.192 0.847 
Quality score 17 608 675 -0.122 -0.551 0.308 0.578 0.818 0.996 0.319 
IL-2           
Publication year 10 357 476 -0.104 -0.370 0.162 0.445 208.478 0.764 0.445 
Sample size 10 357 476 -0.001 -0.020 0.018 0.934 -0.022 -0.021 0.983 
Age mean (MDD) 10 357 476 0.041 -0.123 0.206 0.623 -1.626 -0.510 0.610 
Age mean (HC) 10 357 476 0.057 -0.143 0.257 0.577 -2.110 -0.574 0.566 
Age difference (MDD-HC) 10 357 476 0.031 -0.503 0.565 0.909 -0.141 -0.180 0.857 
Gender % female (MDD) 10 357 476 -0.030 -0.072 0.013 0.174 1.611 1.168 0.243 
Depression severity 10 357 476 0.026 -0.048 0.100 0.486 -2.777 -0.711 0.477 
Country latitude 10 357 476 0.013 -0.029 0.054 0.554 -0.334 -0.446 0.656 
Quality score 10 357 476 -0.190 -1.276 0.897 0.732 0.650 0.289 0.773 
IL-4           
Publication year 10 350 450 0.172 -0.003 0.348 0.054 -347.249 -1.930 0.054 
Sample size 10 350 450 0.005 -0.005 0.015 0.342 -0.970 -1.738 0.082 
Age mean (MDD) 10 350 450 0.024 -0.066 0.114 0.608 -1.493 -0.809 0.419 
Age mean (HC) 10 350 450 0.031 -0.084 0.146 0.599 -1.747 -0.768 0.442 
Age difference (MDD-HC) 10 350 450 0.086 -0.303 0.475 0.666 -0.659 -1.537 0.124 
Gender % female (MDD) 10 350 450 0.005 -0.027 0.036 0.777 -0.838 -0.815 0.415 
Depression severity 10 350 450 -0.034 -0.077 0.010 0.127 3.038 1.278 0.201 
Country latitude 10 350 450 -0.002 -0.025 0.021 0.847 -0.512 -1.082 0.279 
Quality score 10 350 450 -0.102 -0.633 0.429 0.706 -0.197 -0.188 0.851 
sIL-2 receptor           
Publication year 10 489 391 0.021 -0.029 0.070 0.412 -40.590 -0.805 0.421 
Sample size 10 489 391 0.000 -0.007 0.007 0.989 0.744 2.005 0.045 
Gender % female (MDD) 10 489 391 0.006 -0.009 0.021 0.410 0.378 0.789 0.430 
Quality score 10 489 391 -0.205 -0.606 0.195 0.315 1.672 1.763 0.078 
Abbreviations: BMI = body-mass index; CI = confidence interval; ES = effect size; HC = healthy controls; MDD = major depressive disorder; Statistically significant 
results are in bold




df ES 95% CI P-valuea I2 Q P-valueb 
IL-6         
Sample source         
Serum 24 0.485 0.352 0.617 < 0.001 29.2 33.88 0.087 
Plasma 13 0.850 0.570 1.129 < 0.001 80.4 66.46 < 0.001 
Whole blood 2 0.608 0.211 1.004 0.003 49.5 3.96 0.138 
Assay type         
ELISA 36 0.616 0.464 0.768 < 0.001 68.8 115.54 < 0.001 
Other 4 0.622 0.393 0.851 < 0.001 0.0 1.33 0.856 
Age/gender matched         
No 22 0.610 0.415 0.805 < 0.001 68.3 69.36 < 0.001 
Yes 18 0.631 0.442 0.820 < 0.001 62.1 47.49 < 0.001 
Stimulated         
No 38 0.606 0.464 0.748 < 0.001 65.4 109.68 < 0.001 
Yes 2 0.796 0.344 1.249 0.001 64.8 5.67 0.059 
TNF-α         
Sample source         
Serum 27 0.568 0.273 0.862 < 0.001 89.7 263.33 < 0.001 
Plasma 13 0.895 0.454 1.336 < 0.001 90.4 135.05 < 0.001 
Assay type         
ELISA 33 0.639 0.375 0.903 < 0.001 88.7 291.73 < 0.001 
Other 7 0.852 0.209 1.495 0.009 93.7 111.46 < 0.001 
Age/gender matched         
No 22 0.693 0.351 1.035 < 0.001 90.3 227.88 < 0.001 
Yes 18 0.656 0.297 1.016 < 0.001 90.0 180.09 < 0.001 
IL-1β         
Sample source         
Serum 14 -0.151 -0.608 0.306 0.518 91.6 165.90 < 0.001 
Plasma 3 0.555 0.130 0.980 0.011 68.5 9.51 0.023 
Whole blood 2 0.199 -0.053 0.452 0.122 0.0 1.19 0.551 
Age/gender matched         
No 8 -0.142 -0.649 0.365 0.582 88.2 67.88 < 0.001 
Yes 12 0.151 -0.267 0.568 0.479 89.9 119.08 < 0.001 
Stimulated         
No 18 0.002 -0.379 0.382 0.993 90.8 195.28 < 0.001 
Yes 2 0.199 -0.053 0.452 0.122 0.0 1.19 0.551 
IFN-γ         
Sample source         
Serum 11 -0.592 -1.207 0.023 0.059 95.5 245.65 < 0.001 
Plasma 3 0.051 -0.408 0.509 0.829 59.5 7.40 0.060 
Assay type         
ELISA 13 -0.688 -1.171 -0.204 0.005 92.4 171.93 < 0.001 
Other 2 0.475 -0.368 1.319 0.269 93.1 28.89 < 0.001 
Age/gender matched         
No 7 -0.388 -1.131 0.355 0.306 95.2 145.77 < 0.001 
Yes 8 -0.560 -1.172 0.052 0.073 93.1 115.86 < 0.001 
  
IL-10         
Sample source         
Serum 11 0.375 -0.142 0.892 0.155 92.1 138.67 < 0.001 
Plasma 2 0.585 0.328 0.841 < 0.001 0.0 1.77 0.412 
Assay type         
ELISA 12 0.431 -0.060 0.923 0.086 90.9 131.38 < 0.001 
Other 3 0.173 -0.234 0.580 0.404 72.7 11.00 0.012 
Age/gender matched         
No 11 0.528 0.039 1.017 0.034 92.0 136.83 < 0.001 
Yes 4 0.060 -0.318 0.438 0.757 57.4 9.40 0.052 
Drug free during measures         
Yes 9 0.431 -0.167 1.030 0.158 93.1 129.97 < 0.001 
IL-2         
Age/gender matched         
No 4 -0.852 -1.965 0.260 0.133 96.2 104.95 < 0.001 
Yes 4 0.681 -0.688 2.050 0.330 96.3 109.56 < 0.001 
IL-4         
Assay type         
ELISA 6 -0.799 -1.559 -0.040 0.039 91.5 70.21 < 0.001 
Other 2 0.018 -0.610 0.646 0.955 84.1 12.57 0.002 
Age/gender matched         
No 4 0.102 -0.323 0.526 0.639 76.7 17.20 0.002 
Yes 4 -1.234 -2.151 -0.317 0.008 90.6 42.42 < 0.001 
sIL-2 receptor         
Sample source         
Serum 4 0.745 0.242 1.247 0.004 85.4 27.38 < 0.001 
Plasma 2 0.847 0.471 1.224 < 0.001 46.1 3.71 0.157 
Age/gender matched         
No 2 0.753 0.479 1.028 < 0.001 0.0 1.40 0.498 
Yes 6 0.706 0.254 1.159 0.002 84.4 38.45 < 0.001 
CCL-2         
Age/gender matched         
No 2 4.122 0.533 7.711 0.024 98.4 123.03 < 0.001 
Yes 4 0.727 -0.219 1.673 0.132 93.4 60.20 < 0.001 
sIL-6 receptor         
Age/gender matched         
No 2 0.289 -0.192 0.771 0.238 64.9 5.69 0.058 
Yes 3 0.380 -0.165 0.925 0.171 79.2 14.44 0.002 
IL-8         
Assay type         
ELISA 3 0.127 -0.259 0.512 0.520 50.9 6.11 0.106 
Other 2 -0.073 -0.789 0.642 0.841 88.5 17.46 < 0.001 
Age/gender matched         
No 2 0.159 -0.410 0.728 0.584 74.8 7.95 0.019 
Yes 3 -0.062 -0.565 0.441 0.810 77.6 13.41 0.004 
Abbreviations: CI = confidence interval; ES = effect size; Statistically significant results are in bold 
a In Z-test of overall effect 
b In Q-test of heterogeneity 
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Supplementary Figure S36. Cummulative meta-analysis of studies that investigated soluble TNF receptor 2 
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